Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Group 1 - Collegium Pharmaceuticals (NASDAQ: COLL) stock is trading at over $30 per share, with a market capitalization just shy of $1 billion [1] - The company provides insights for both novice and experienced biotech investors, including catalysts to watch for and buy/sell ratings [1] - The investing group Haggerston BioHealth offers detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [1] Group 2 - The Q1 2025 quarterly report/10Q submission is referenced, indicating ongoing financial disclosures [1]